Syncom Formulations (India) Ltd
NSE: SYNCOMF BSE: 524470
₹13.24
(-2.58%)
Thu, 19 Feb 2026, 07:51 am
Market Cap12.88B
PE Ratio18.05
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KSyncom Formulations (India) Analysis
dividend
- Unable to calculate sustainability of dividends as Syncom Formulations (India) has not reported any payouts.
- Unable to evaluate Syncom Formulations (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Syncom Formulations (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Syncom Formulations (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
- Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (98.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 9.3x debt.
- Syncom Formulations (India)'s cash and other short term assets cover its long term commitments.
- Syncom Formulations (India) earns more interest than it pays, coverage of interest payments is not a concern.
- Syncom Formulations (India)'s level of debt (6.3%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (5.5% vs 6.3% today).
- High level of physical assets or inventory.
management
- The average tenure for the Syncom Formulations (India) board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Vijay's remuneration is lower than average for companies of similar size in India.
- Vijay's compensation has been consistent with company performance over the past year, both up more than 20%.
- More shares have been bought than sold by Syncom Formulations (India) individual insiders in the past 3 months.
- The average tenure for the Syncom Formulations (India) management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Syncom Formulations (India) is not covered by any analysts.
- Syncom Formulations (India) has significant price volatility in the past 3 months.
past
- Syncom Formulations (India)'s 1-year earnings growth exceeds its 5-year average (22% vs 5.1%)
- Syncom Formulations (India)'s year on year earnings growth rate has been positive over the past 5 years.
- Syncom Formulations (India) used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Syncom Formulations (India)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Syncom Formulations (India) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Syncom Formulations (India)'s earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (22% vs 22.7%).
value
- Syncom Formulations (India) is good value based on assets compared to the IN Pharmaceuticals industry average.
- Syncom Formulations (India) is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Syncom Formulations (India) is good value based on earnings compared to the India market.
- 524470 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524470 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524470 is up 54.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524470 is up 54.9% outperforming the market in India which returned 8% over the past month.
- Syncom Formulations (India)'s share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Syncom Formulations (India)'s share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800